Suven life bags three product patents for CNS molecules
CNS molecules could be used for treating various central nervous system disorders.
New Delhi, May 10, 2013: Suven Life Sciences has received a total of three product patents for CNS molecules, which could be used for treating various central nervous system disorders.
It may be noted that the product patents (two from Canada and one from Eurasia) are valid till 2028. The company has received approval for molecules that could be used in treatment of Parkinson, Alzheimer's disease and Schizophrenia.
With these patents, the company has a total of 12 patents from Canada and 13 from Eurasia.